Zhi-Xin Shan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Zhi-Xin Shan has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Qiu-Xiong Lin
Guangdong Cardiovascular Institute, Guangdong Provincial Key Laboratory of Clinical Pharmacology, Guangzhou 510080, China
18 shared publicationsJie-Ning Zhu
Key Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
15 shared publicationsYong-Heng Fu
Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, China
14 shared publicationsXi-Yong Yu
13 shared publications- Chun-Yu Deng
Research Center of Medical Sciences, Guangdong Provincial People's Hospital, Guangzhou 510080, PR China
12 shared publications Hui Li
Key Laboratory of Clinical Pharmacology Guangdong Provincial Health Commission, Medical Research Institute, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, China
7 shared publications
Latest Publications
- Open Access
- 10 July 2026
- Published by OAE Publishing Inc. in Vessel Plus
- Vol. 10
Circular RNAs as potential therapeutics and novel biomarkers for heart failure
Heart failure (HF) is a type of chronic pathological remodeling in which the heart fails to efficiently supply an adequate amount of blood to fulfill the body’s requirements. Circular RNAs (circRNAs) are recognized as specific types of long noncoding RNAs that are involved in the regulation of the pathogenesis of cardiovascular diseases, including cardiac remodeling and HF. In this review, knowledge about the origin, characteristics, and function of circRNAs is summarized. The regulatory function of circRNAs in cardiac remodeling mechanisms, including cell death, cardiac hypertrophy, fibrosis and mitochondrial metabolism, is reviewed. Finally, future directions for investigating the diagnostic and pharmacological potential of circRNAs in HF are proposed.
- 10 July 2026
- Published by OAE Publishing Inc. in Vessel Plus
- Vol. 10
Open AccessCircular RNAs as potential therapeutics and novel biomarkers for heart failure
Heart failure (HF) is a type of chronic pathological remodeling in which the heart fails to efficiently supply an adequate amount of blood to fulfill the body’s requirements. Circular RNAs (circRNAs) are recognized as specific types of long noncoding RNAs that are involved in the regulation of the pathogenesis of cardiovascular diseases, including cardiac remodeling and HF. In this review, knowledge about the origin, characteristics, and function of circRNAs is summarized. The regulatory function of circRNAs in cardiac remodeling mechanisms, including cell death, cardiac hypertrophy, fibrosis and mitochondrial metabolism, is reviewed. Finally, future directions for investigating the diagnostic and pharmacological potential of circRNAs in HF are proposed.
- 11 June 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (9) , 1-14
S1UTRSP5, a short restructured RNA from SLIT1 3′UTR, mitigates mouse cardiac remodeling via enhancing SlRT1 activity
The 3′ untranslated regions (3′UTRs) have been known to regulate mRNA location, stability, and translation. 3′UTR length regulation is involved in the pathogenesis of cardiac dysfunction; however, more about the roles of 3′UTRs in cardiac remodeling remains elusive. In this study, we found slit guidance ligand 1 (SLIT1) 3′UTR with 3074 nt in length, which was 10-fold higher than SLIT1 coding sequence (CDS), was significantly decreased in the myocardium of patients with heart failure (HF) (n = 40) in comparison with healthy organ donors (n=17). We revealed that SLIT1 3′UTR and the 1526 nt fragment of SLIT1 3′UTR (FS1UTR) mainly and specifically combined miR-34a-5p, and improved cardiac remodeling through the miR-34a-5p/SIRT1 axis independently of Slit1 expression. Furthermore, a 260 nt restructured RNA derived from FS1UTR, S1UTRSP5, which contains 5 binding sites of miR-34a-5p seed sequence, alleviated cardiac remodeling in vitro and in vivo. We demonstrated that S1UTRSP5 blocked the function of miR-34a-5p and activated the SIRT1-PGC-1α-Nrf2 axis in cardiomyocytes, and promoted the SIRT1/Smad3 signal in cardiac fibroblasts and the SIRT1-eNOS-VEGFA axis in endothelial cells, collectively contributing to the amelioration of cardiac remodeling. These results provide new insights into the development of S1UTRSP5 as a novel inhibitor of miR-34a-5p for cardiac remodeling and HF. The alternative text for this image may have been generated using AI. The human SLIT1 3′UTR or FS1UTR combines miR-34a-5p to increase SIRT1 level in CMs, CFs and ECs. Notably, S1UTRSP5, a 260-nt stable RNA derived from SLIT1 3′UTR, efficiently sponged miR-34a-5p to activate SIRT1-PGC-1α-Nrf2 pathway in CMs, and to promote SIRT1/Smad3 signal in CFs and the SIRT1-eNOS-VEGFA pathway in ECs, collectively contributing to amelioration of cardiac remodeling.
- 11 June 2026
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (9) , 1-14
S1UTRSP5, a short restructured RNA from SLIT1 3′UTR, mitigates mouse cardiac remodeling via enhancing SlRT1 activity
The 3′ untranslated regions (3′UTRs) have been known to regulate mRNA location, stability, and translation. 3′UTR length regulation is involved in the pathogenesis of cardiac dysfunction; however, more about the roles of 3′UTRs in cardiac remodeling remains elusive. In this study, we found slit guidance ligand 1 (SLIT1) 3′UTR with 3074 nt in length, which was 10-fold higher than SLIT1 coding sequence (CDS), was significantly decreased in the myocardium of patients with heart failure (HF) (n = 40) in comparison with healthy organ donors (n=17). We revealed that SLIT1 3′UTR and the 1526 nt fragment of SLIT1 3′UTR (FS1UTR) mainly and specifically combined miR-34a-5p, and improved cardiac remodeling through the miR-34a-5p/SIRT1 axis independently of Slit1 expression. Furthermore, a 260 nt restructured RNA derived from FS1UTR, S1UTRSP5, which contains 5 binding sites of miR-34a-5p seed sequence, alleviated cardiac remodeling in vitro and in vivo. We demonstrated that S1UTRSP5 blocked the function of miR-34a-5p and activated the SIRT1-PGC-1α-Nrf2 axis in cardiomyocytes, and promoted the SIRT1/Smad3 signal in cardiac fibroblasts and the SIRT1-eNOS-VEGFA axis in endothelial cells, collectively contributing to the amelioration of cardiac remodeling. These results provide new insights into the development of S1UTRSP5 as a novel inhibitor of miR-34a-5p for cardiac remodeling and HF. The alternative text for this image may have been generated using AI. The human SLIT1 3′UTR or FS1UTR combines miR-34a-5p to increase SIRT1 level in CMs, CFs and ECs. Notably, S1UTRSP5, a 260-nt stable RNA derived from SLIT1 3′UTR, efficiently sponged miR-34a-5p to activate SIRT1-PGC-1α-Nrf2 pathway in CMs, and to promote SIRT1/Smad3 signal in CFs and the SIRT1-eNOS-VEGFA pathway in ECs, collectively contributing to amelioration of cardiac remodeling.
- 28 July 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (1) , 86-102
circSP199a, a circularized RNA sponge targeting miR-199a-5p and -3p, mitigates mouse cardiac hypertrophy and fibrosis
Increasing evidence shows that microRNAs (miRNAs) are functionally associated with cardiac remodeling. Functionally, some cytoplasmic circRNAs may act as miRNA sponges to inhibit functions of the combined miRNAs. Our previous study showed that miR-199a-5p and -3p promote cardiac hypertrophy and fibrosis. In this study, we designed and synthesized a novel circularized RNA sponge, circSP199a, and evaluated the therapeutic effects of circSP199a against cardiac hypertrophy and fibrosis. The synthesized circSP199a included 6 repeats of reverse complements of seed sequences of miR-199a-5p and -3p with 515 nt in length. We showed that the synthesized circSP199a and expression vector-mediated circSP199a expression inhibited cardiomyocyte hypertrophy and mitigated the fibrotic phenotypes in neonatal mouse cardiac fibroblasts and human cardiac organoid fibrosis via the combination of miR-199a-5p and -3p. Furthermore, intravenous injection of AAV9-circSP199a for 21 days in advance significantly ameliorated transverse aortic constriction-induced cardiac injury and remodeling in mice. We demonstrated that circSP199a blocked the functions of miR-199a-5p and -3p to enhance the expression of target genes of PGC-1α, Rb1, Sirt1 and Smad1 both in vitro and in vivo. These results provide new insights into the development of RNA sponge-based therapies for cardiac hypertrophy and fibrosis. The artificial circSP199a functions as a novel inhibitor of miR-199a-5p and -3p, exogenous provision of circSP199a specifically sponges miR-199a-5p and -3p to block their functions with subsequent upregulations of the target genes, including PGC-1α, Rb1, SIRT1 and Smad1, to mitigate the pathological cardiac hypertrophy and fibrosis.
- 28 July 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 47 (1) , 86-102
circSP199a, a circularized RNA sponge targeting miR-199a-5p and -3p, mitigates mouse cardiac hypertrophy and fibrosis
Increasing evidence shows that microRNAs (miRNAs) are functionally associated with cardiac remodeling. Functionally, some cytoplasmic circRNAs may act as miRNA sponges to inhibit functions of the combined miRNAs. Our previous study showed that miR-199a-5p and -3p promote cardiac hypertrophy and fibrosis. In this study, we designed and synthesized a novel circularized RNA sponge, circSP199a, and evaluated the therapeutic effects of circSP199a against cardiac hypertrophy and fibrosis. The synthesized circSP199a included 6 repeats of reverse complements of seed sequences of miR-199a-5p and -3p with 515 nt in length. We showed that the synthesized circSP199a and expression vector-mediated circSP199a expression inhibited cardiomyocyte hypertrophy and mitigated the fibrotic phenotypes in neonatal mouse cardiac fibroblasts and human cardiac organoid fibrosis via the combination of miR-199a-5p and -3p. Furthermore, intravenous injection of AAV9-circSP199a for 21 days in advance significantly ameliorated transverse aortic constriction-induced cardiac injury and remodeling in mice. We demonstrated that circSP199a blocked the functions of miR-199a-5p and -3p to enhance the expression of target genes of PGC-1α, Rb1, Sirt1 and Smad1 both in vitro and in vivo. These results provide new insights into the development of RNA sponge-based therapies for cardiac hypertrophy and fibrosis. The artificial circSP199a functions as a novel inhibitor of miR-199a-5p and -3p, exogenous provision of circSP199a specifically sponges miR-199a-5p and -3p to block their functions with subsequent upregulations of the target genes, including PGC-1α, Rb1, SIRT1 and Smad1, to mitigate the pathological cardiac hypertrophy and fibrosis.
- Open Access
- 11 March 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (8) , 2180-2195
CircSARS-CV2-N1368 from SARS-CoV-2 impairs endothelial cell function through the upregulation of ATF7 to activate TLR4/NF-κB/ROS signaling
SARS-CoV-2 can encode circular RNAs (circRNAs); however, the potential effects of exogenous SARS-CoV-2 circRNAs on cardiovascular sequelae remain unknown. Three circRNAs derived from the nucleocapsid (N) gene of SARS-CoV-2, namely, circSARS-CV2-Ns, were identified for functional studies. In particular, circSARS-CV2-N1368 was shown to enhance platelet adhesiveness to endothelial cells (ECs) and inhibit EC-dependent vascular relaxation. Moreover, exogenous expression of circSARS-CV2-N1368 suppressed EC proliferation and migration and decreased angiogenesis and cardiac organoid beating. Mechanistically, we elucidated that circSARS-CV2-N1368 sponged the microRNA miR-103a-3p, which could reverse circSARS-CV2-N1368-induced EC damage. Additionally, activating transcription factor 7 (ATF7) was identified as a target gene of miR-103a-3p, and Toll-like receptor 4 (TLR4) was verified as a downstream gene of ATF7 that mediates circARS-CV2-N1368-induced activation of nuclear factor kappa B (NF-κB) signaling and ROS production in ECs. Importantly, the reactive oxygen species (ROS) scavenger NAC mitigated the circSARS-CV2-N1368-promoted EC impairment. Our findings reveal that the TLR4/NF-κB/ROS signal pathway is critical for mediating circSARS-CV2-N1368-promoted oxidative damage in ECs, providing insights into the endothelial impairment caused by circSARS-CV2-Ns.
- 11 March 2025
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 46 (8) , 2180-2195
Open AccessCircSARS-CV2-N1368 from SARS-CoV-2 impairs endothelial cell function through the upregulation of ATF7 to activate TLR4/NF-κB/ROS signaling
SARS-CoV-2 can encode circular RNAs (circRNAs); however, the potential effects of exogenous SARS-CoV-2 circRNAs on cardiovascular sequelae remain unknown. Three circRNAs derived from the nucleocapsid (N) gene of SARS-CoV-2, namely, circSARS-CV2-Ns, were identified for functional studies. In particular, circSARS-CV2-N1368 was shown to enhance platelet adhesiveness to endothelial cells (ECs) and inhibit EC-dependent vascular relaxation. Moreover, exogenous expression of circSARS-CV2-N1368 suppressed EC proliferation and migration and decreased angiogenesis and cardiac organoid beating. Mechanistically, we elucidated that circSARS-CV2-N1368 sponged the microRNA miR-103a-3p, which could reverse circSARS-CV2-N1368-induced EC damage. Additionally, activating transcription factor 7 (ATF7) was identified as a target gene of miR-103a-3p, and Toll-like receptor 4 (TLR4) was verified as a downstream gene of ATF7 that mediates circARS-CV2-N1368-induced activation of nuclear factor kappa B (NF-κB) signaling and ROS production in ECs. Importantly, the reactive oxygen species (ROS) scavenger NAC mitigated the circSARS-CV2-N1368-promoted EC impairment. Our findings reveal that the TLR4/NF-κB/ROS signal pathway is critical for mediating circSARS-CV2-N1368-promoted oxidative damage in ECs, providing insights into the endothelial impairment caused by circSARS-CV2-Ns.
- Open Access
- 3 March 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (3) , 634-649
New Types of Post-Translational Modification of Proteins in Cardiovascular Diseases
Post-translational modifications (PTMs), which are covalent alterations of proteins after their synthesis, are critical for their proper function and the maintenance of cellular physiology. The significance of PTMs in the context of cardiovascular diseases (CVDs) has been increasingly recognized due to their potential to influence protein stability, activity, and localization, thereby affecting the progression of CVDs. The identification and understanding of PTMs in CVDs at the molecular level are vital for the discovery of new biomarkers and new targets for clinical interventions. This article provides a comprehensive overview of the role and mechanisms of new types of PTMs, such as acetylation, crotonylation, succinylation, S-nitrosylation, malonylation, S-palmitonylation, β-hydroxybutyrylation and lactylation, in CVDs, highlighting their importance in advancing diagnostic and therapeutic approaches for CVDs. Graphical Abstract
- 3 March 2025
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 18 (3) , 634-649
Open AccessNew Types of Post-Translational Modification of Proteins in Cardiovascular Diseases
Post-translational modifications (PTMs), which are covalent alterations of proteins after their synthesis, are critical for their proper function and the maintenance of cellular physiology. The significance of PTMs in the context of cardiovascular diseases (CVDs) has been increasingly recognized due to their potential to influence protein stability, activity, and localization, thereby affecting the progression of CVDs. The identification and understanding of PTMs in CVDs at the molecular level are vital for the discovery of new biomarkers and new targets for clinical interventions. This article provides a comprehensive overview of the role and mechanisms of new types of PTMs, such as acetylation, crotonylation, succinylation, S-nitrosylation, malonylation, S-palmitonylation, β-hydroxybutyrylation and lactylation, in CVDs, highlighting their importance in advancing diagnostic and therapeutic approaches for CVDs. Graphical Abstract
- Open Access
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e032961
Prognostic Value of Depressive Symptoms for Cardiovascular Events in Female Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
Background: Among those with heart failure (HF), women are more likely to develop depression than men. Few studies have focused on the outcomes of female patients with HF with depressive symptoms. Methods and Results: A total of 506 female patients with HF with preserved ejection fraction were included in this secondary analysis from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) cohort, and 439 female patients with HF with reduced ejection fraction were included from the HF‐ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) cohort. Depressive symptoms were measured using the Patient Health Questionnaire‐9 and Beck Depression Inventory‐II. The depression class was categorized by severity, and the change in clinical depression class was defined as aggravated (1‐grade increase) or improved (1‐grade decrease). The prognostic value of depressive symptoms was determined by using multivariable Cox proportional hazards models. Female patients with improved depressive symptoms had worse depressive status at baseline and lower baseline Kansas City Cardiomyopathy Questionnaire scores. Depression class at the 12‐month visit and depression class change were the dominant prognostic factors for cardiovascular death in female patients with HF with preserved ejection fraction (hazard ratio [HR], 1.43 [95% CI, 1.02–2.01], P =0.036; HR, 1.71 [95% CI, 1.14–2.55], P =0.009). Among the patients with HF with reduced ejection fraction, both the depression class at baseline and depression class change had significant prognostic effects on cardiovascular death (HR, 3.30 [95% CI, 1.70–6.39], P P =0.004). However, the prognostic value of depressive assessments for hospitalization in patients with HF is unclear. Conclusions: In female patients with HF with reduced ejection fraction, the depression class at baseline was most strongly associated with cardiovascular death, whereas in female patients with HF with preserved ejection fraction, the change in depression class exhibited a more significant prognostic trend.
- 7 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (9) , e032961
Open AccessPrognostic Value of Depressive Symptoms for Cardiovascular Events in Female Patients With Heart Failure With Reduced Ejection Fraction and Heart Failure With Preserved Ejection Fraction
Background: Among those with heart failure (HF), women are more likely to develop depression than men. Few studies have focused on the outcomes of female patients with HF with depressive symptoms. Methods and Results: A total of 506 female patients with HF with preserved ejection fraction were included in this secondary analysis from the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist) cohort, and 439 female patients with HF with reduced ejection fraction were included from the HF‐ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) cohort. Depressive symptoms were measured using the Patient Health Questionnaire‐9 and Beck Depression Inventory‐II. The depression class was categorized by severity, and the change in clinical depression class was defined as aggravated (1‐grade increase) or improved (1‐grade decrease). The prognostic value of depressive symptoms was determined by using multivariable Cox proportional hazards models. Female patients with improved depressive symptoms had worse depressive status at baseline and lower baseline Kansas City Cardiomyopathy Questionnaire scores. Depression class at the 12‐month visit and depression class change were the dominant prognostic factors for cardiovascular death in female patients with HF with preserved ejection fraction (hazard ratio [HR], 1.43 [95% CI, 1.02–2.01], P =0.036; HR, 1.71 [95% CI, 1.14–2.55], P =0.009). Among the patients with HF with reduced ejection fraction, both the depression class at baseline and depression class change had significant prognostic effects on cardiovascular death (HR, 3.30 [95% CI, 1.70–6.39], P P =0.004). However, the prognostic value of depressive assessments for hospitalization in patients with HF is unclear. Conclusions: In female patients with HF with reduced ejection fraction, the depression class at baseline was most strongly associated with cardiovascular death, whereas in female patients with HF with preserved ejection fraction, the change in depression class exhibited a more significant prognostic trend.
- 14 March 2022
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 15 (3) , 548-559
Suppression of the Inhibitory Effect of circ_0036176-Translated Myo9a-208 on Cardiac Fibroblast Proliferation by miR-218-5p
Increasing evidence has shown that circular RNAs (circRNAs) participate in the process of cardiac remodeling. CircRNA circ_0036176 originating from the back-splicing of exon 2 to exon4 of myosin IXA (Myo9a) gene was shown to be increased in the myocardium of patients with heart failure (HF) and riched in exosomes from human AC16 cardiomyocytes with overexpression of circ_0036176. Proliferation activity was inhibited in mCFs subjected to exosomal circ_0036176 treatment and in mCFs with overexpression of circ_0036176. Interestingly, circ_0036176 contains an IRES element and an ORF of 627 nt encoding a 208-amino acid protein (termed as Myo9a-208). Myo9a-208 was shown to mediate the inhibitory effect of circ_0036176 on CFs proliferation, and miR-218-5p could inhibit Myo9a-208 expression by binding to circ_0036176, resulting in abolishing the effect of circ_0036176 on inactivating cyclin/Rb signal and suppressing CFs proliferation. Our findings suggest that circ_0036176 inhibits mCFs proliferation by translating Myo9a-208 protein to suppress cyclin/Rb pathway. Graphical abstract
- 14 March 2022
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 15 (3) , 548-559
Suppression of the Inhibitory Effect of circ_0036176-Translated Myo9a-208 on Cardiac Fibroblast Proliferation by miR-218-5p
Increasing evidence has shown that circular RNAs (circRNAs) participate in the process of cardiac remodeling. CircRNA circ_0036176 originating from the back-splicing of exon 2 to exon4 of myosin IXA (Myo9a) gene was shown to be increased in the myocardium of patients with heart failure (HF) and riched in exosomes from human AC16 cardiomyocytes with overexpression of circ_0036176. Proliferation activity was inhibited in mCFs subjected to exosomal circ_0036176 treatment and in mCFs with overexpression of circ_0036176. Interestingly, circ_0036176 contains an IRES element and an ORF of 627 nt encoding a 208-amino acid protein (termed as Myo9a-208). Myo9a-208 was shown to mediate the inhibitory effect of circ_0036176 on CFs proliferation, and miR-218-5p could inhibit Myo9a-208 expression by binding to circ_0036176, resulting in abolishing the effect of circ_0036176 on inactivating cyclin/Rb signal and suppressing CFs proliferation. Our findings suggest that circ_0036176 inhibits mCFs proliferation by translating Myo9a-208 protein to suppress cyclin/Rb pathway. Graphical abstract
- Open Access
- 20 October 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 26, 1035-1050
Diverging targets mediate the pathological role of miR-199a-5p and miR-199a-3p by promoting cardiac hypertrophy and fibrosis
- 20 October 2021
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 26, 1035-1050
Open AccessDiverging targets mediate the pathological role of miR-199a-5p and miR-199a-3p by promoting cardiac hypertrophy and fibrosis
- 15 March 2021
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 14 (6) , 1051-1062
Dickkopf 3: a Novel Target Gene of miR-25-3p in Promoting Fibrosis-Related Gene Expression in Myocardial Fibrosis
Increasing evidence has shown that microRNAs (miRNAs) participate in cardiac fibrosis. We aimed to elucidate the effect of miRNA miR-25-3p on cardiac fibrosis. MiRNA microarray was used to profile miRNAs in the myocardium of angiotensin-II (Ang-II)-infused mice. Effect of miR-25-3p on expression of fibrosis-related genes, including Col1a1, Col3a1, and Acta2, was investigated both in vitro and in vivo. MiR-25-3p was shown increased in the myocardium of Ang-II-infused mice and patients with heart failure. MiR-25-3p enhanced fibrosis-related gene expression in mouse cardiac fibroblasts (mCFs) and in the myocardium of Ang-II-infused mice. Dickkopf 3 (Dkk3) was identified as a target gene of miR-25-3p, and Dkk3 could ameliorate Smad3 activation and fibrosis-related gene expression via enhancing Smad7 expression in mCFs. Additionally, NF-κB signal was proven to mediate upregulation of miR-25-3p in cardiac fibrosis. Our findings suggest that miR-25-3p enhances cardiac fibrosis by suppressing Dkk3 to activate Smad3 and fibrosis-related gene expression. Graphical abstract
- 15 March 2021
- Published by Springer Nature in Journal of Cardiovascular Translational Research
- Vol. 14 (6) , 1051-1062
Dickkopf 3: a Novel Target Gene of miR-25-3p in Promoting Fibrosis-Related Gene Expression in Myocardial Fibrosis
Increasing evidence has shown that microRNAs (miRNAs) participate in cardiac fibrosis. We aimed to elucidate the effect of miRNA miR-25-3p on cardiac fibrosis. MiRNA microarray was used to profile miRNAs in the myocardium of angiotensin-II (Ang-II)-infused mice. Effect of miR-25-3p on expression of fibrosis-related genes, including Col1a1, Col3a1, and Acta2, was investigated both in vitro and in vivo. MiR-25-3p was shown increased in the myocardium of Ang-II-infused mice and patients with heart failure. MiR-25-3p enhanced fibrosis-related gene expression in mouse cardiac fibroblasts (mCFs) and in the myocardium of Ang-II-infused mice. Dickkopf 3 (Dkk3) was identified as a target gene of miR-25-3p, and Dkk3 could ameliorate Smad3 activation and fibrosis-related gene expression via enhancing Smad7 expression in mCFs. Additionally, NF-κB signal was proven to mediate upregulation of miR-25-3p in cardiac fibrosis. Our findings suggest that miR-25-3p enhances cardiac fibrosis by suppressing Dkk3 to activate Smad3 and fibrosis-related gene expression. Graphical abstract